Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count

Abstract

Atypical hemolytic uremic syndrome (aHUS) in childhood is a rare disease with frequent progression to end-stage renal disease and a high recurrence after kidney transplantation. Eculizumab, a humanized monoclonal antibody that binds to complement protein C5, may be beneficial in the treatment of aHUS. A 6-year-old girl developed aHUS with only slightly… (More)
DOI: 10.1007/s00467-012-2130-z

Topics

2 Figures and Tables

Slides referencing similar topics